Monday, March 17, 2025 | 01:43 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Drugmaker Mylan's profit rises 6%; sets no timeline on strategic options

US generic drugmakers such as Mylan and Teva Pharmaceutical Industries Ltd have suffered over the past few years as a steep fall in generic prices weighed on their bottom lines

drugs
Premium

Photo: Shutterstock

Reuters
Mylan NV beat analysts' estimates for third-quarter profit on Monday, as the generic drugmaker reported higher sales of its products in emerging markets and said it had not set any timeline on evaluating its strategic alternatives.

The company's shares rose 6 percent to $33.59 in after-market trading.

The EpiPen maker in August had set up a committee to review possible strategic alternatives, citing a tough US environment for generic drugmakers.

"I can assure you the board is busy looking at lots of things... But we put no timeframes around that," Chief Executive Officer Heather Bresch said on a post-earnings call.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in